Kidney Navigator, home

Research briefing

New kidney disease news and research, in plain words, with a link to where each item came from. Newest first.

Last updated · Written by Michael Moore

National Kidney Foundation asks Congress to expand Medigap access for people under 65

National Kidney Foundation (NKF) ·

NKF wrote to a U.S. senator on September 24, 2026, asking for a federal right to buy Medigap (Medicare Supplement) coverage for people under 65 who qualify for Medicare because of kidney failure, along with protections to keep premiums affordable. NKF says federal law does not guarantee that access and that at least 15 states do not guarantee it either.

Keep in mind: this is a request from an advocacy group. It is not a law and nothing has changed in the rules yet.

Read the source (opens in a new tab)

NKF Innovation Fund invests in a gene-editing company

NKF press release ·

NKF announced an investment in Nephrogen, a company developing one-time gene-editing therapies. Its first program is for polycystic kidney disease (ADPKD) and a second is for APOL1-related kidney disease. The release says the company reported results in mouse models and in donated human kidneys, and that the mouse work is still under peer review.

Keep in mind: this is early research and a press release from an investor. The release itself says no gene therapy is approved for any kidney disease.

Read the source (opens in a new tab)

Pharmacy groups back a newer kidney-function equation for medicine decisions

NKF educational article for health professionals ·

A consensus statement endorsed by five U.S. pharmacy organizations recommends using the 2021 CKD-EPI eGFR equation, instead of the older Cockcroft-Gault equation, for medication-related decisions. NKF says the older formula was built from a small group of White men and depends on body weight.

Keep in mind: this is written for clinicians and is about how health systems set up their tools. Your own medicine doses are for your care team and pharmacist to decide.

Read the source (opens in a new tab)

NKF genetics summit looks at genetic testing in everyday kidney care

NKF press release ·

NKF held a Genetics in Kidney Health Summit in Dallas on September 18-19, 2026. A main message was that genetic testing should reach beyond a few specialty centers, with community nephrologists helping. Sessions also covered testing for relatives, living kidney donors, privacy, insurance and access.

Keep in mind: this reports a meeting, not a study or a new guideline.

Read the source (opens in a new tab)

Virtual CKD programs showed mixed results in a new assessment

NKF press release, describing a Peterson Health Technology Institute (PHTI) assessment ·

NKF reports that PHTI found no consistent evidence that the virtual CKD programs it assessed slowed disease progression or lowered overall health care spending, though they helped some people start dialysis in a planned setting. PHTI called for earlier identification and more primary care involvement, and estimates that 87% of people with CKD do not know they have it.

Keep in mind: this is NKF’s account of the PHTI report, and NKF also promotes its own program in the same release.

Read the source (opens in a new tab)

Pig-kidney transplants discussed at a Capitol Hill roundtable

NKF news story ·

On September 15, 2026, NKF brought officials, clinicians, ethicists and a transplant recipient together to discuss kidney xenotransplantation, the use of a genetically modified pig kidney. NKF says it is in clinical trials and that nearly 90,000 Americans are waiting for a kidney. Safety, long-term outcomes, infection risk, access, cost and equity were raised.

Keep in mind: this is a discussion event. It is not a treatment available outside a clinical trial.

Read the source (opens in a new tab)

What people on dialysis told NKF about phosphorus and transplant

NKF news story ·

In an NKF survey of people on dialysis, 44% said meeting their phosphorus goal was at least somewhat hard, 55% said managing phosphorus affected daily life at least moderately, and 79% had been told at some point that their level was too high. NKF says the patient survey did not show that high phosphorus consistently blocks a transplant waitlist spot, while a separate survey of health professionals suggested it can create challenges.

Keep in mind: these are survey answers, not a trial. Each transplant center sets its own criteria, so questions about your own case belong with your care team.

Read the source (opens in a new tab)

KDIGO Direct newsletter, September 2026

KDIGO ·

KDIGO’s monthly update lists new publications on IgA nephropathy, B-cell therapies and CKM, an article on kidney paired exchange in Germany, conference news including TTS 2026, and new educational activities.

Keep in mind: I have only read the headlines on KDIGO’s page, not the publications behind them.

Read the source (opens in a new tab)

How each item is handled

  • It comes from a named public source, such as the National Kidney Foundation, KDIGO, the CDC or a published study.
  • It shows the source name, the source’s date and a link you can open yourself.
  • It says what the source reported and no more. A survey is not a trial, a request to Congress is not a law, and early research is not a treatment you can get today.
  • It never promises a result and never tells you what to do about your own care. It may suggest a question to bring to your care team.

Why some items wait

If I cannot open an item’s source and read it, I do not publish the item. I hold it until the source loads. A summary of a summary is how mistakes get passed along, and this is health information.

See something wrong?

Email michael@mavtg.com with the item and what you think it should say. Please do not send health information about yourself or anyone else.

More on how this site sources and reviews its information is on the editorial policy page. Related: glossary · CKD white paper · Doctor visit planner.